DRUG
LY3305677
Administered SC
A Study of LY3305677 in Participants With Obesity Or Overweight
Status
Completed
Phase
Phase 1
Enrollment
32
Locations
3
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Nov 21, 2022
Study start
Nov 16, 2022
Primary completion
Jun 27, 2023
Study completion
Jun 27, 2023
Results posted
Not reported
Registry updated
Jul 5, 2023
Outcomes
What the study measures.
Primary outcomes
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame · Baseline through Week 20
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Secondary outcomes
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3305677
Time frame · Predose up to 72 hours postdose
PK: Cmax of LY3305677
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3305677
Time frame · Predose up to 72 hours postdose
PK: AUC of LY3305677
Pharmacodynamics (PD): Percentage change in Body Weight
Time frame · Baseline through Week 20
PD: Percentage change in Body Weight
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Participants with stable weight for 3 months and body mass index of 27.0 and 50.0 kilograms per square meter (kg/m²) Exclusion Criteria: * Have history of type 1 diabetes mellitus or type 2 diabetes mellitus, ketoacidosis, or hyperosmolar state or coma
Study locations
3 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Anaheim Clinical Trials, LLC
Anaheim, California, United States
ICON Early Phase Services
San Antonio, Texas, United States
ICON Early Phase Services Lenexa Center
Salt Lake City, Utah, United States
Publications
Results and literature.
Related trials
More studies on Mazdutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
West China Hospital · Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis
Phase 2 / Phase 3
Not yet recruiting
60
2026-07
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Tianjin Medical University · Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
Not applicable
Not yet recruiting
72
2026-07
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Eli Lilly · Alcohol Use Disorder
Phase 2
Completed
308
2026-07
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
China National Center for Cardiovascular Diseases · Obesity & Overweight · Coronary Heart Disease
Phase 4
Not yet recruiting
116
2026-06
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
Shandong Provincial Hospital · Prediabetes · Impaired Fasting Glucose
Phase 4
Not yet recruiting
150
2026-06
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes · Obesity
Phase 3
Completed
349
2026-06
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
200
2026-06
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.